Açık Akademik Arşiv Sistemi

Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study

Show simple item record

dc.contributor.authors Bilir, C; Yildiz, I; Bilici, A; Ucar, M; Berk, V; Yildiz, Y; Yazici, O; Imamoglu, GI; Karadurmus, N; Pilanci, KN; Arpaci, E; Tanriverdi, O; Karci, E; Temiz, S; Nayir, E; Oktay, E; Dal, P; Petekkaya, I; Varim, C; Cinemre, H;
dc.date.accessioned 2020-02-27T08:26:51Z
dc.date.available 2020-02-27T08:26:51Z
dc.date.issued 2017
dc.identifier.citation Bilir, C; Yildiz, I; Bilici, A; Ucar, M; Berk, V; Yildiz, Y; Yazici, O; Imamoglu, GI; Karadurmus, N; Pilanci, KN; Arpaci, E; Tanriverdi, O; Karci, E; Temiz, S; Nayir, E; Oktay, E; Dal, P; Petekkaya, I; Varim, C; Cinemre, H; (2017). Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. CANCER INVESTIGATION, 35, 255-248
dc.identifier.issn 0735-7907
dc.identifier.uri https://doi.org/10.1080/07357907.2017.1292518
dc.identifier.uri https://hdl.handle.net/20.500.12619/65884
dc.description.abstract Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.
dc.language English
dc.publisher TAYLOR & FRANCIS INC
dc.subject Oncology
dc.title Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study
dc.type Article
dc.identifier.volume 35
dc.identifier.startpage 248
dc.identifier.endpage 255
dc.contributor.department Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor Bilir, Cemil
dc.contributor.saüauthor Varım, Ceyhun
dc.contributor.saüauthor Cinemre, Hakan
dc.relation.journal CANCER INVESTIGATION
dc.identifier.wos WOS:000399505100004
dc.identifier.doi 10.1080/07357907.2017.1292518
dc.identifier.eissn 1532-4192
dc.contributor.author Bilir, Cemil
dc.contributor.author Ibrahim Yildiz
dc.contributor.author Ahmet Bilici
dc.contributor.author Mahmut Ucar
dc.contributor.author Veli Berk
dc.contributor.author Yasar Yildiz
dc.contributor.author Ozan Yazici
dc.contributor.author Goksen Inanc Imamoglu
dc.contributor.author Nuri Karadurmus
dc.contributor.author Kezban Nur Pilanci
dc.contributor.author Erkan Arpaci
dc.contributor.author Ozgur Tanriverdi
dc.contributor.author Ebru Karci
dc.contributor.author Suleyman Temiz
dc.contributor.author Erdinc Nayir
dc.contributor.author Esin Oktay
dc.contributor.author Pinar Dal
dc.contributor.author Ibrahim Petekkaya
dc.contributor.author Varım, Ceyhun
dc.contributor.author Cinemre, Hakan


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record